These results additionally suggest that alterations in osteoblast protein expression are correlated with the type of breast cancer cell treatment, where osteoblasts treated with triple-negative BCCM exhibited a different protein expression profile than osteoblasts treated with ER+ luminal BCCM. This evidence concerns the gene ESR1 and breast cancer.